pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Novo Nordisk Inc · news · pharmadog
← back to Novo Nordisk Inc
News mentioning Novo Nordisk Inc
167
stories
May 6, 26
STAT+: Oregon hospitals won’t outsource to national physician chain after all
stat
May 6, 26
STAT+: Color Health moving deeper into cancer services, complete with virtual ‘tumor boards’
stat
May 6, 26
Novo hikes guidance on Wegovy pill’s fast sales start
biopharma dive
May 6, 26
STAT+: How a global effort to explore the ‘dark proteome’ is upending our understanding of human disease
stat
May 6, 26
STAT+: Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share price
stat
May 6, 26
Novo Nordisk's Q1 in four words: Pills, pricing, payments and pressure
endpoints
May 4, 26
STAT+: French regulator fines Novo and Lilly over weight loss ad campaigns
stat
May 1, 26
Amgen launches late-stage obesity trial in patients who switch from rival drugs
endpoints
May 1, 26
STAT+: Pharmalittle: We’re reading about obesity drugs and a compounding list, an AstraZeneca setback, and more
stat
Apr 30, 26
STAT+: FDA wants to exclude weight loss drugs from a compounding list
stat
Apr 30, 26
Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch
biopharma dive
Apr 28, 26
Boehringer dual-acting obesity shot hits mark in Phase 3 trial
biopharma dive
Apr 28, 26
Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.
biopharma dive
Apr 24, 26
Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics
biopharma dive
Apr 23, 26
Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs
biopharma dive
Apr 23, 26
Novo's pill for kids; Altimmune’s $225M offering; Merck teams with Google Cloud
endpoints
Apr 22, 26
An ‘AI scientist’ can tackle drug R&D. What does that mean for pharma?
biopharma dive
← prev
page 6 of 6
next →
